Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/21705
Title: NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
Authors: Hardcastle, Nicholas;Hofman, Michael S;Lee, Ching-Yu;Callahan, Jason;Selbie, Lisa;Foroudi, Farshad;Shaw, Mark;Chander, Sarat;Lim, Andrew;Chesson, Brent;Murphy, Declan G;Kron, Tomas;Siva, Shankar
Affiliation: Division of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Austin Health, Heidelberg, Victoria, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3000, Australia
Department of Radiation Therapy, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, 2522, Australia
Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
Issue Date: 5-Sep-2019
EDate: 2019-09-05
Citation: Radiation oncology 2019; 14(1): 164
Abstract: In prostate cancer patients, imaging of bone metastases is enhanced through the use of sodium fluoride positron emission tomography (18F-NaF PET/CT). This imaging technique shows areas of enhanced osteoblastic activity and blood flow. In this work, 18F-NaF PET/CT was investigated for response assessment to single fraction stereotactic ablative body radiotherapy (SABR) to bone metastases in prostate cancer patients. Patients with bone metastases in a prospective trial treated with single fraction SABR received a 18F-NaF PET/CT scan prior to and 6 months post-SABR. The SUVmax in the tumour was determined and the difference between before and after SABR determined. The change in uptake in the non-tumour bone was also measured as a function of the received SABR dose. Reduction in SUVmax was observed in 29 of 33 lesions 6 months after SABR (mean absolute decrease in SUVmax 17.7, 95% CI 25.8 to - 9.4, p = 0.0001). Of the three lesions with increased SUVmax post-SABR, two were from the same patient and located in the vertebral column. Both were determined to be local progression in addition to one fracture. The third lesion (in a rib) was shown to be controlled locally but suffered from a fracture at 24 months. Progression adjacent to the treated volume was observed in two patients. The non-tumour bone irradiated showed increased loss in uptake with increasing dose, with a median loss in uptake of 23.3% for bone receiving 24 Gy. 18F-NaF PET/CT for response assessment of bone metastases to single fraction SABR indicates high rates of reduction of osteoblastic activity in the tumour and non-tumour bone receiving high doses. The occurrence of marginal recurrence indicates use of larger clinical target volumes may be warranted in treatment of bone metastases. POPSTAR, 'Pilot Study of patients with Oligometastases from Prostate cancer treated with STereotactic Ablative Radiotherapy', Universal Trial Number U1111-1140-7563 , Registered 17th April 2013.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21705
DOI: 10.1186/s13014-019-1359-0
ORCID: 0000-0001-7796-8472
0000-0001-8387-0965
PubMed URL: 31488175
Type: Journal Article
Subjects: Imaging
Metastases
NaF
PET
Prostate cancer
SABR
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.